Back to resultsPhotodynamic Therapy With Verteporfin for Corneal Neovascularization
Primary Purpose
Corneal Neovascularization
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Photodynamic Therapy with Verteporfin
Sponsored by
About this trial
This is an interventional treatment trial for Corneal Neovascularization
Eligibility Criteria
Inclusion Criteria:
- Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month
Exclusion Criteria:
- Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00471406
First Posted
May 8, 2007
Last Updated
October 16, 2008
Sponsor
Chonnam National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00471406
Brief Title
Photodynamic Therapy With Verteporfin for Corneal Neovascularization
Study Type
Interventional
2. Study Status
Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Chonnam National University Hospital
4. Oversight
5. Study Description
Brief Summary
Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.
Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment.
Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured.
Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Neovascularization
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Photodynamic Therapy with Verteporfin
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Eligibility Criteria
Inclusion Criteria:
Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month
Exclusion Criteria:
Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyung chul Yoon, MD
Organizational Affiliation
Chonnam natianl university hospital
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Photodynamic Therapy With Verteporfin for Corneal Neovascularization
We'll reach out to this number within 24 hrs